Pharma in Brief’s 2023 Year in Review and Trends for 2024
Pharma in Brief
JANUARY 10, 2024
Expected highlights for 2024 include a final PTA regime, more details on PMPRB drug pricing guidelines and national pharmacare, and fall-out from the US mass drug importation program targeting Canadian medicines. The PMPRB reviews the prices of patented medicines to ensure that they are not sold at “excessive” prices.
Let's personalize your content